Redeye comments on Cereno Scientific’s Q3 2022 report. We believe the company’s operations relating to activities aiming at bringing its preclinical candidates into the clinic, protecting its core assets, and the commencement of the clinical phase II trial in PAH with CS1 as well as the TO2 exercise have the potential to strengthen the case. We reiterate our base case of SEK5.8 per share.

Länk till analysen